A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2011
08/17/2011	EP2356091A2 Substituted amido phenoxybenzamides
08/17/2011	EP2356090A2 Crystalline forms of fingolimod hcl
08/17/2011	EP2355853A1 Biodegradable polymer - bioactive moiety conjugates
08/17/2011	EP2355852A1 Chemically modified cell-penetrating peptides for improved delivery of gene modulating compounds
08/17/2011	EP2355851A1 Novel lipids and compositions for the delivery of therapeutics
08/17/2011	EP2355838A2 Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
08/17/2011	EP2355835A1 Use of escin for treatment of type iv hypersensitivity reaction
08/17/2011	EP2355833A2 Fas/fasl or other death receptor targeted methods and compositions for killing tumor cells
08/17/2011	EP2355832A2 Compositions and methods for treating retrovirus infections
08/17/2011	EP2355831A1 Use of inkt or tlr agonists for protecting against or treating a disease such as acute infection or cancer
08/17/2011	EP2355830A1 Compositions comprising a calcium channel blocker or a calmodulin blocker for use in the removal of hyperplastic skin lesions
08/17/2011	EP2355829A1 Combination of insulin with triazine derivatives and its use for treating diabetes
08/17/2011	EP2355828A1 Therapies for hematologic malignancies
08/17/2011	EP2355827A2 Methods of treating thalassemia
08/17/2011	EP2355826A1 Compounds and methods of promoting oligodendrocyte precursor differentiation
08/17/2011	EP2355825A2 Compounds for the treatment of inflammatory disorders
08/17/2011	EP2355824A2 Method for reducing thrombocytopenia and thrombocytopenia-associated mortality
08/17/2011	EP2355823A1 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
08/17/2011	EP2355822A1 Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzoýb¨thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
08/17/2011	EP2355821A1 P70 s6 kinase inhibitor and egfr inhibitor combination therapy
08/17/2011	EP2355820A1 P70 s6 kinase inhibitor and mtor inhibitor combination therapy
08/17/2011	EP2355819A2 Treating cancer by modulating a mnk
08/17/2011	EP2355818A2 Methods and compositions for treating status epilepticus and seizures causing status epilepticus
08/17/2011	EP2355817A1 Heterocyclic gamma secretase modulators
08/17/2011	EP2355816A2 Novel uses
08/17/2011	EP2355815A1 Use of leukotriene inhibitors for treating lung diseases in prematurely born infants
08/17/2011	EP2355814A2 Pyrones for the treatment of metabolic disorders
08/17/2011	EP2355813A1 Fat emulsion for artificially feeding seriously ill intensive care patients
08/17/2011	EP2355812A2 A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis
08/17/2011	EP2355811A2 Therapeutic compositions
08/17/2011	EP2355810A2 Methods for preventing or reducing carcinogenesis or oxidative stress
08/17/2011	EP2355809A1 Methods for preventing or reducing colon carcinogenesis
08/17/2011	EP2355808A2 Arformoterol and tiotropium compositions and methods for use
08/17/2011	EP2355807A1 Inhibitors of dimethylarginine dimethylaminohydrolase
08/17/2011	EP2355805A1 Rifaximin complexes
08/17/2011	EP2355804A1 Quetiapine composition
08/17/2011	EP2355802A1 Intermediate and oral administrative formats containing lenalidomide
08/17/2011	EP2355801A1 Statin nanoparticles
08/17/2011	EP2355800A1 Nanoparticles of beta-lactam derivatives
08/17/2011	EP2355796A2 Salicylic acid composition
08/17/2011	EP2355660A1 Compositions and methods for treating multiple sclerosis
08/17/2011	EP2355659A1 Fused heterocyclic m1 receptor positive allosteric modulators
08/17/2011	EP2355657A1 Compositions and methods of treating endothelial disorders
08/17/2011	EP2268644B1 Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
08/17/2011	EP2231598B1 Novel diazeniumdiolate derivatives, method for the preparation thereof and pharmaceutical compositions containing the same
08/17/2011	EP2225231B1 Aminotriazole derivatives as alx agonists
08/17/2011	EP2222631B1 Substituted phenylmethyl bicyclocarboxyamide compounds
08/17/2011	EP2190836B1 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
08/17/2011	EP2188268B1 Substituted piperazinyl pyrazines and pyridines as 5-ht7 receptor antagonists
08/17/2011	EP2167494B1 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives
08/17/2011	EP2129216B1 Production of a viable, storable worm egg suspension
08/17/2011	EP2117542B1 Combinations of beta- 2 -adrenoceptor agonistic benzothiazolone
08/17/2011	EP2094656B1 P<0}{0pyrrol derivatives, preparation and use of the same in therapy<0}
08/17/2011	EP2091919B1 Derivatives of 18-amino substituted analogs of the geldamycin hydroquinon with cytotoxic activity for the treatment of cancer
08/17/2011	EP2081927B1 Piperidine derivatives as renin inhibitors
08/17/2011	EP2010531B1 Spirocyclic cyclohexane derivatives with analgesic properties
08/17/2011	EP2010490B1 Crystalline forms of a dimethylphenyl compound
08/17/2011	EP1976561B1 Anti-infective solution comprising a compound of pyrido(3,2,1-ij)-benzoxadiazine type
08/17/2011	EP1966129B1 Carbonates of fenicol antibiotics
08/17/2011	EP1945734B1 Polycationic viscoelastic compositions
08/17/2011	EP1915151B1 Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
08/17/2011	EP1904455B1 Pyridazine derivatives
08/17/2011	EP1904053B1 Isoflavone nanoparticles and use thereof
08/17/2011	EP1896422B1 Tyrosine kinase inhibitors
08/17/2011	EP1893608B1 Thiazolyl mglur5 antagonists and methods for their use
08/17/2011	EP1885717B1 Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases
08/17/2011	EP1871382B1 Methods for the treatment of central nervous system injury via a tapered administration of progesterone
08/17/2011	EP1848425B1 Therapeutic combinations of manidi pine and simvastatin
08/17/2011	EP1819686B1 5-hydroxy-benzothiazole derivatives having beta-2-adrenorecptor agonist activity
08/17/2011	EP1812389B1 Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
08/17/2011	EP1808170B1 Aqueous eye drops with accelerated intraocular migration
08/17/2011	EP1797048B1 Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
08/17/2011	EP1781619B1 Sigma receptor inhibitors
08/17/2011	EP1773775B1 Six-membered heterocycles useful as serine protease inhibitors
08/17/2011	EP1771441B1 Novel carboxamides for use as xa inhibitors
08/17/2011	EP1761505B1 Pyrimidine urea derivatives as kinase inhibitors
08/17/2011	EP1725223B1 Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
08/17/2011	EP1687295B1 Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
08/17/2011	EP1685137B1 Particle-forming compositions containing fused pyrrolocarbazoles
08/17/2011	EP1668144B1 Nucleotide sequences promoting the trans-membrane transport of nucleic acids
08/17/2011	EP1644330B1 Quaternary nitrogen heterocyclic compounds for detecting aqueous monosaccharides in physiological fluids
08/17/2011	EP1638509B1 Thermally stable crystalline epirubicin hydrochloride and method of making the same
08/17/2011	EP1610612B1 Endosomolytic polymers
08/17/2011	EP1599209B1 Inhalation composition
08/17/2011	EP1572200B1 Aminoindazole derivatives and use thereof as kinase inhibitors
08/17/2011	EP1562571B1 Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection
08/17/2011	EP1511713B1 Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments
08/17/2011	EP1507558B1 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
08/17/2011	EP1485360B1 Sodium channel blockers
08/17/2011	EP1474134B1 Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ramipril for preventing or blocking heart failure
08/17/2011	EP1444233B1 A2b adenosine receptor antagonists
08/17/2011	EP1419768B1 Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction
08/17/2011	EP1404841B1 Cyp1b1 nucleic acids and methods of use
08/17/2011	EP1402253B1 A process for the isolation of a major harmful oxidant from cigarette smoke
08/17/2011	EP1381348B1 Skin-protective compositions effective against vesicants and percutaneous chemical agents
08/17/2011	EP1379507B1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS
08/17/2011	EP1327003B1 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
08/17/2011	EP1246808B1 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
08/17/2011	EP0853618B1 Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) n- (aminoiminomethyl)phenylalkyl -azaheterocyclylamide compounds
08/17/2011	CN201930267U 新型蜂药挂片 The new drug coupon bee

1 ... 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 ... 7860